株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

欧州の皮膚置換、代用、活性創傷修復モジュレータ市場

European Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators

発行 Medtech Insight 商品コード 128316
出版日 ページ情報 英文 168 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
欧州の皮膚置換、代用、活性創傷修復モジュレータ市場 European Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators
出版日: 2010年08月24日 ページ情報: 英文 168 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

欧州の皮膚置換、代用、活性創傷修復モジュレータ市場は2009年に3億9,100万米ドルとなり、今後もCAGR9.2%で拡大し、2013年には5億5,700万米ドル近くに達するとみられています。

当レポートは、同市場の現状と製品概要、技術動向とともに将来の予測について、欧州主要諸国の概要とともにまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 欧州の医療市場

  • EU
  • 各国の医療プロファイル
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国

第2章 創傷管理における臨床上の課題

  • 創傷閉鎖の生理学
    • 皮膚層と補助構造
    • 創傷閉鎖プロセス
  • 影響因子
    • 外的要因
    • 内的要因
    • 創傷治療の合併症
  • 主な創傷の種類

第3章 皮膚置換および代用市場

  • 同種移植片
  • 自家移植片
  • 異種移植片
  • 羊膜
  • 自家・組織エンジニアド皮膚置換と代用
  • 開発中の製品
  • 市場分析
  • 競合分析

第4章 活性創傷修復モジュレータ市場

  • 局所的抗菌剤
    • 製品
    • 市場分析
    • 競合分析
  • 成長因子
    • 分類
    • 製品
    • 市場分析
  • 遺伝子療法分析
  • その他
    • 抗生物質および抗感染剤
    • ホルモン
    • マトリクス・メタロプロテイナーゼ酵素阻害剤
    • 糖尿病性創傷における神経ペプチド
    • 幹細胞
    • その他の製品

第5章 企業プロファイル

付録:企業リスト

目次
Product Code: A136

Over the past two decades, dramatic advances have been made in the management of wound patients. These factors have greatly improved the ability of clinicians to overcome many of the previously irresolvable issues associated with the treatment of acute and chronic wounds. In 2009, European sales of skin replacements and substitutes and active wound repair modulators totaled approximately $391 million, with skin replacements and substitutes accounting for 48% of sales and active wound repair modulators accounting for the remaining 52% of sales. Over the forecast period covered by this report, total sales are expected to increase at a compound annual rate of 9.2%, reaching approximately $557 in the year 2013.

This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European skin replacements and substitutes and active wound repair modulators market. Major topics covered by this report include an overview of the healthcare markets of France, Germany, Italy, Spain, and the United Kingdom; an overview of clinical issues in wound management; skin replacement and substitutes including allografts, autografts, xenografts, amniotic membranes, and autologous and tissue-engineered skin replacements and substitutes (e.g., epidermal, dermal, and composite bilayer skin equivalents); and active wound repair modulators including topical antimicrobials, growth factors, gene therapy agents, antibiotics/anti-infectives, hormones, matrix metalloproteinase enzyme inhibitors, neuropeptides, and stem cells.

Table of Contents

EXECUTIVE SUMMARY

  • i. Clinical Issues in Wound Management
  • ii. Skin Replacements and Substitutes
    • a. Allografts
    • b. Autografts
    • c. Xenografts
    • d. Amniotic Membranes
    • e. Skin Equivalents
    • f. Skin Replacements and Substitutes, Market Analysis
  • iii. Active Wound Repair Modulators
    • a. Topical Antimicrobial Products
    • b. Growth Factors
    • c. Other Active Wound Repair Modulators
    • d. Active Wound Repair Modulators, Market Analysis
  • iv. Combined Market Analysis
    • a. Market Drivers
    • b. Market Limiters
    • c. Combined Market Forecast
  • Exhibit ES-1: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013
  • Exhibit ES-2: Europe, Active Wound Repair Modulators, Market Forecast, by Country, 2008-2013
  • Exhibit ES-3: Europe, Skin Replacements and Substitutes and Active Wound Repair Modulators, Combined Market Forecast, by Country, 2008-2013

1. EUROPEAN HEALTHCARE MARKETS

  • 1.1 The European Union
    • 1.1.1 A Common Currency
    • 1.1.2 Regulatory Policies
    • 1.1.3 Reimbursement
    • 1.1.4 Healthcare Spending
  • 1.2 Selected European National Healthcare Profiles
    • 1.2.1 France
      • 1.2.1.1 Healthcare Organization and Reform
      • 1.2.1.2 Hospital Services
      • 1.2.1.3 Medical Device Reimbursement
    • 1.2.2 Germany
      • 1.2.2.1 Healthcare Organization and Reform
      • 1.2.2.2 Hospital Services
      • 1.2.2.3 Medical Device Reimbursement
    • 1.2.3 Italy
      • 1.2.3.1 Healthcare Organization and Reform
      • 1.2.3.2 Hospital Services
      • 1.2.3.3 Medical Device Reimbursement
    • 1.2.4 Spain
      • 1.2.4.1 Healthcare Organization and Reform
      • 1.2.4.2 Hospital Services
      • 1.2.4.3 Medical Device Reimbursement
    • 1.2.5 United Kingdom
      • 1.2.5.1 Healthcare Organization and Reform
      • 1.2.5.2 Hospital Services
      • 1.2.5.3 Medical Device Reimbursement
  • Exhibit 1-1: European Union, Medical Devices Risk Classification System
  • Exhibit 1-2: European Union Population Statistics Comparison for the Years 1999, 2009, and 2019
  • Exhibit 1-3: France, Selected National Healthcare Statistics
  • Exhibit 1-4: Germany, Selected National Healthcare Statistics
  • Exhibit 1-5: Italy, Selected National Healthcare Statistics
  • Exhibit 1-6: Spain, Selected National Healthcare Statistics
  • Exhibit 1-7: United Kingdom, Selected National Healthcare Statistics

2. CLINICAL ISSUES IN WOUND MANAGEMENT

  • 2.1 Physiology of Wound Closure
    • 2.1.1 Layers of the Skin and Supporting Structures
      • 2.1.1.1 Epidermis
      • 2.1.1.2 Dermis
      • 2.1.1.3 Subcutaneous Tissue
      • 2.1.1.4 Fascia
      • 2.1.1.5 Muscle
      • 2.1.1.6 Bone
    • 2.1.2 Wound Closure Process
      • 2.1.2.1 Hemostasis
      • 2.1.2.2 Inflammation
      • 2.1.2.3 Proliferation
      • 2.1.2.4 Remodeling Phase
  • 2.2 Factors Affecting Wound Closure
    • 2.2.1 Extrinsic Factors
      • 2.2.1.1 Desiccation
      • 2.2.1.2 Hydration
      • 2.2.1.3 Infection
      • 2.2.1.4 Maceration
      • 2.2.1.5 Medication and Other Treatment Modalities
      • 2.2.1.6 Necrotic Tissue and Debris
      • 2.2.1.7 Oxygenation
      • 2.2.1.8 Stress
      • 2.2.1.9 Temperature
      • 2.2.1.10 Wound Creation and Depth
      • 2.2.1.11 Wound Closure Techniques
      • 2.2.1.12 Other Extrinsic Factors
    • 2.2.2 Intrinsic Factors
      • 2.2.2.1 Body Build
      • 2.2.2.2 Chronic Illness and Age
      • 2.2.2.3 Nutrition
    • 2.2.3 Complications of Wound Healing
      • 2.2.3.1 Bleeding
      • 2.2.3.2 Scarring
  • 2.3 Major Wound Types
    • 2.3.1 Amputation
    • 2.3.2 Arterial Ulcers
    • 2.3.3 Burns
    • 2.3.4 Diabetic Ulcers
    • 2.3.5 Pressure Ulcers
    • 2.3.6 Surgical Wounds
    • 2.3.7 Traumatic Wounds
    • 2.3.8 Venous Ulcers
  • Exhibit 2-1: The Skin' s Layers and Supporting Structures
  • Exhibit 2-2: Phases of the Wound Closure Process
  • Exhibit 2-3: Extrinsic and Intrinsic Factors Affecting Wound Closure
  • Exhibit 2-4: Major Wound Types, by Cause
  • Exhibit 2-5: Stages of Burn Wounds
  • Exhibit 2-6: Stages of Pressure Ulcers
  • Exhibit 2-7: 2008, Europe, Surgical Procedure Volumes, by Type

3. SKIN REPLACEMENTS AND SUBSTITUTES MARKET

  • 3.1 Allografts
  • 3.2 Autografts
  • 3.3 Xenografts
  • 3.4 Amniotic Membranes
  • 3.5 Autologous and Tissue-Engineered Skin Replacements and Substitutes
    • 3.5.1 Epidermal Equivalents
    • 3.5.2 Dermal Equivalents
    • 3.5.3 Composite Bilayer Skin Equivalents
  • 3.6 Skin Substitute Products under Development
    • 3.6.1 Advanced BioHealing
    • 3.6.2 Healthpoint/DFB Pharmaceuticals
    • 3.6.3 Organogenesis
    • 3.6.4 Dr. Suwelack Skin & Health Care
  • 3.7 Market Analysis
  • 3.8 Competitive Analysis
  • Exhibit 3-1: Advantages and Disadvantages of Allografts
  • Exhibit 3-2: 2010, Selected Epidermal Equivalent Skin Substitutes
  • Exhibit 3-3: 2010, Selected Dermal Equivalent Skin Substitutes
  • Exhibit 3-4: 2010, Selected Composite Bilayer Equivalent Skin Substitutes
  • Exhibit 3-5: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013
  • Exhibit 3-6: 2009, Europe, Skin Replacements and Substitutes Market, Share by Supplier

4. ACTIVE WOUND REPAIR MODULATORS MARKET

  • 4.1 Topical Antimicrobials
    • 4.1.1 Products
    • 4.1.2 Market Analysis
    • 4.1.3 Competitive Analysis
  • 4.2 Growth Factors
    • 4.2.1 Classification of Growth Factors
      • 4.2.1.1 Fibroblast Growth Factors
      • 4.2.1.2 Transforming Growth Factors
      • 4.2.1.3 Epidermal Growth Factors
      • 4.2.1.4 Platelet-Derived Growth Factors
      • 4.2.1.5 Insulin-Like Growth Factors
      • 4.2.1.6 Keratinocyte Growth Factors
      • 4.2.1.7 Vascular Endothelial Growth Factors
      • 4.2.1.8 Autologous Growth Factors
        • 4.2.1.8.1 Arteriocyte Medical Systems
        • 4.2.1.8.2 Cytomedix
        • 4.2.1.8.3 Harvest Technologies
      • 4.2.1.9 Angiogenic Growth Factors
    • 4.2.2 Products
    • 4.2.3 Market Analysis
  • 4.3 Gene Therapy Agents
  • 4.4 Other Active Wound Repair Modulators
    • 4.4.1 Antibiotics and Anti-Infectives
      • 4.4.1.1 Basilea Pharmaceutica
      • 4.4.1.2 Cerexa/Forest Laboratories
      • 4.4.1.3 Cubist Pharmaceuticals
      • 4.4.1.4 Helix BioMedix
      • 4.4.1.5 Theravance
    • 4.4.2 Hormones
    • 4.4.3 Matrix Metalloproteinase Enzyme Inhibitors
      • 4.4.3.1 Dermagenics/Greystone Pharmaceuticals
      • 4.4.3.2 Smith & Nephew
      • 4.4.3.3 Systagenix Wound Management
    • 4.4.4 Neuropeptides in Diabetic Wounds
    • 4.4.5 Stem Cells
    • 4.4.6 Other Products
      • 4.4.6.1 Kingfisher Healthcare
      • 4.4.6.2 Pioneer Surgical Orthobiologics/Pioneer Surgical Technology
      • 4.4.6.3 RegeneRx Biopharmaceuticals
  • Exhibit 4-1: 2010, Selected Topical Antimicrobial Products
  • Exhibit 4-2: Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2008-2013
  • Exhibit 4-3: 2009, Europe, Topical Antimicrobial Products, Share by Supplier
  • Exhibit 4-4: 2010, Selected Growth Factors in Development for Wound Healing Applications
  • Exhibit 4-5: 2010, Selected Angiogenic Growth Factors
  • Exhibit 4-6: Europe, Growth Factors Used in Wound Healing Applications, Market Forecast, by Country, 2008-2013

5. COMPANY PROFILES

  • 5.1 Advanced BioHealing, Inc.
  • 5.2 Cook Biotech, Inc./Cook Group, Inc.
  • 5.3 Cytomedix, Inc.
  • 5.4 Fidia Advanced Biopolymers SRL/Anika Therapeutics, Inc.
  • 5.5 GlaxoSmithKline PLC
  • 5.6 Integra LifeSciences Corporation
  • 5.7 LEO Pharma AS/LEO Foundation
  • 5.8 sanofi-aventis
  • 5.9 Smith & Nephew PLC.
  • 5.10 Systagenix Wound Management LTD.

APPENDIX: COMPANY LISTING

Back to Top